\n\nMaterials and Methods Pregnancies at risk for fetal Hb Bart’s disease scheduled for cordocentesis at 18 to 22 weeks were recruited into the study. Maternal serum-free beta-hCG, PAPP-A, and AFP concentrations were measured before cordocentesis, and the final fetal diagnosis
of Hb Bart disease was based on fetal Hb typing using high-performance liquid chromatography.\n\nResults Of 57 recruited pregnancies, 11 had fetal Hb Bart’s disease and 46 were unaffected. Maternal serum alpha-fetoprotein (MSAFP) concentrations were significantly higher in women with fetal Hb Bart’s disease than those with unaffected fetuses (median 99.53 vs 50.83, P < 0.001), whereas the concentrations of free beta-hCG and PAPP-A were not significantly different between the two groups (P = 0.543 and 0.777, respectively).\n\nConclusion Ralimetinib clinical trial Second-trimester MSAFP may be clinically a useful screening test for fetal Hb Bart’s disease among BMS-777607 solubility dmso pregnancies at risk. Copyright (C) 2011 John Wiley & Sons, Ltd.”
“BACKGROUND. Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are common abnormalities in elderly men. It is considered that epithelial stem cells are involved
in the etiology and development of both diseases. To distinguish aberrant from normal cells, the knowledge about primary epithelial stem/progenitor cells (ES/P) is essential. The aim of this study was to examine the role of surface markers to distinguish between different subsets of prostate basal epithelium.\n\nMETHODS. The expression pattern of prostate tissue single cell suspensions was analyzed by flow cytometry using different markers. Sorted cell populations were examined for their clonogenic capacity and the resulted colonies were analyzed with flow cytometry, Western blot, and qPCR for stem cell, basal, and luminal epithelium markers. Additionally, the histological localization of the examined markers was determined using immunofluorescence.\n\nRESULTS.
Using the combination of CD49f, Trop-2, and surface CD24, basal cell subsets with distinct differentiation capacities were dissected (CD49f(+)Trop-2(+)CD24(-) Selleckchem MK-8931 and CD49f(+)Trop-2(+)CD24(+)). Although cells from the two subsets gave rise to similar basal colonies, qPCR of primary tissue revealed that higher levels of basal marker expression were detected in the CD49f(+)Trop-2(+)CD24(-) subset. Immunofluorescence analysis showed a prominent expression of CD24 by luminal and basal cells.\n\nCONCLUSIONS. Subsets with distinct differentiation capacities within the basal epithelium (CD49f(+)Trop-2(+)CD24(-) and CD49f(+)Trop-2(+)CD24(+)) can be distinguished in human prostate.